Top

Cancer Cell International

Published in:

Open Access 01-12-2021 | Primary research

Development and validation of ferroptosis-related lncRNAs prognosis signatures in kidney renal clear cell carcinoma

Authors: Xiao-Liang Xing, Zhi-Yong Yao, Jialan Ou, Chaoqun Xing, Feng Li

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

Ferroptosis is a recently recognised new type of cell death which may be a potential target for cancer therapy. In the present study, we aimed to screen ferroptosis-related differentially expressed long non-coding RNAs as biomarkers to predict the outcome of kidney renal clear cell carcinoma.

Methods

RNAseq count data and corresponding clinical information were obtained from the Cancer Genome Atlas database. Lists of ferroptosis-related genes and long non-coding RNAs were obtained from the FerrDb and GENCODE databases, respectively. The candidate prognostic signatures were screened by Cox regression analyses and least absolute shrinkage and selection operator analyses.

Results

Three ferroptosis-related long non-coding RNAs (DUXAP8, LINC02609, and LUCAT1) were significantly correlated with the overall survival of kidney renal clear cell carcinoma independently. Kidney renal clear cell carcinoma patients with high-risk values displayed worse OS. Meanwhile, the expression of these three ferroptosis-related long non-coding RNAs and their risk scores were significantly correlated with clinicopathological features. Principal component analyses showed that patients with kidney renal clear cell carcinoma have differential risk values were well distinguished by the three ferroptosis-related long non-coding RNAs.

Conclusions

The present study suggests that the risk assessment model constructed by these three ferroptosis-related long non-coding RNAs could accurately predict the outcome of kidney renal clear cell carcinoma. We also provide a novel perspective for cancer prognosis screening.

Available only for authorised users

Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Bai X, Yi M, Dong B, Zheng X, Wu K. The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017. Exp Hematol Oncol. 2020;9:27. https://doi.org/10.1186/s40164-020-00181-3.CrossRefPubMedPubMedCentral

Hu F, Zeng W, Liu X. A gene signature of survival prediction for kidney renal cell carcinoma by multi-omic data analysis. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20225720.CrossRefPubMedPubMedCentral

Hsieh JJ, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. https://doi.org/10.1038/nrdp.2017.9.CrossRefPubMedPubMedCentral

Dixon SJ. Ferroptosis: bug or feature? Immunol Rev. 2017;277:150–7. https://doi.org/10.1111/imr.12533.CrossRefPubMed

Yagoda N, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864–8. https://doi.org/10.1038/nature05859.CrossRefPubMedPubMedCentral

Yu H, Guo P, Xie X, Wang Y, Chen G. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med. 2017;21:648–57. https://doi.org/10.1111/jcmm.13008.CrossRefPubMed

Latunde-Dada GO. Ferroptosis: role of lipid peroxidation, iron and ferritinophagy. Biochim Biophys Acta Gen Subj. 1861;1893–1900:2017. https://doi.org/10.1016/j.bbagen.2017.05.019.CrossRef

Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73:2195–209. https://doi.org/10.1007/s00018-016-2194-1.CrossRefPubMedPubMedCentral

10.

Xie Y, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369–79. https://doi.org/10.1038/cdd.2015.158.CrossRefPubMedPubMedCentral

11.

Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72. https://doi.org/10.1016/j.cell.2012.03.042.CrossRefPubMedPubMedCentral

12.

Sharma P, Shimura T, Banwait JK, Goel A. Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of beta-catenin/Wnt-signaling pathways in colorectal cancer. Carcinogenesis. 2020;41:1385–94. https://doi.org/10.1093/carcin/bgaa090.CrossRefPubMedPubMedCentral

13.

Markowitsch SD, et al. Artesunate inhibits growth of sunitinib-resistant renal cell carcinoma cells through cell cycle arrest and induction of ferroptosis. Cancers. 2020. https://doi.org/10.3390/cancers12113150.CrossRefPubMedPubMedCentral

14.

Zhang H, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19:43. https://doi.org/10.1186/s12943-020-01168-8.CrossRefPubMedPubMedCentral

15.

Fearnhead HO, Vandenabeele P, Vanden Berghe T. How do we fit ferroptosis in the family of regulated cell death? Cell Death Differ. 2017;24:1991–8. https://doi.org/10.1038/cdd.2017.149.CrossRefPubMedPubMedCentral

16.

Wu P, et al. Feasibility of cultivation of Spinibarbus sinensis with coconut oil and its effect on disease resistance (nonspecific immunity, antioxidation and mTOR and NF-kB signaling pathways). Fish Shellfish Immunol. 2019;93:726–31. https://doi.org/10.1016/j.fsi.2019.06.052.CrossRefPubMed

17.

Su Y, et al. Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Lett. 2020;483:127–36. https://doi.org/10.1016/j.canlet.2020.02.015.CrossRefPubMed

18.

Xie B, Guo Y. Molecular mechanism of cell ferroptosis and research progress in regulation of ferroptosis by noncoding RNAs in tumor cells. Cell Death Discov. 2021;7:101. https://doi.org/10.1038/s41420-021-00483-3.CrossRefPubMedPubMedCentral

19.

Iyer MK, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47:199–208. https://doi.org/10.1038/ng.3192.CrossRefPubMedPubMedCentral

20.

Han P, et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature. 2014;514:102–6. https://doi.org/10.1038/nature13596.CrossRefPubMedPubMedCentral

21.

Tang X, et al. Long non-coding RNA (lncRNA) CRNDE regulated lipopolysaccharides (LPS)-induced MRC-5 inflammation injury through targeting MiR-141. Med Sci Monit. 2020;26: e920928. https://doi.org/10.12659/MSM.920928.CrossRefPubMedPubMedCentral

22.

Zhai W, et al. LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ. 2017;24:1502–17. https://doi.org/10.1038/cdd.2017.74.CrossRefPubMedPubMedCentral

23.

Xiao ZD, et al. Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. Nat Commun. 2017;8:783. https://doi.org/10.1038/s41467-017-00902-z.CrossRefPubMedPubMedCentral

24.

Dong JS, Wu B, Jiang B. LncRNA SNHG7 promotes the proliferation and inhibits apoptosis of renal cell cancer cells by downregulating CDKN1A. Eur Rev Med Pharmacol Sci. 2019;23:10241–7. https://doi.org/10.26355/eurrev_201912_19661.CrossRefPubMed

25.

You BH, et al. HERES, a lncRNA that regulates canonical and noncanonical Wnt signaling pathways via interaction with EZH2. Proc Natl Acad Sci USA. 2019;116:24620–9. https://doi.org/10.1073/pnas.1912126116.CrossRefPubMedPubMedCentral

26.

Li Y, et al. Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nat Commun. 2020;11:1000. https://doi.org/10.1038/s41467-020-14802-2.CrossRefPubMedPubMedCentral

27.

Mou Y, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34. https://doi.org/10.1186/s13045-019-0720-y.CrossRefPubMedPubMedCentral

28.

Porta C, et al. The adjuvant treatment of kidney cancer: a multidisciplinary outlook. Nat Rev Nephrol. 2019;15:423–33. https://doi.org/10.1038/s41581-019-0131-x.CrossRefPubMed

29.

Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193–205. https://doi.org/10.1016/j.ctrv.2007.12.001.CrossRefPubMed

30.

Turajlic S, Swanton C, Boshoff C. Kidney cancer: the next decade. J Exp Med. 2018;215:2477–9. https://doi.org/10.1084/jem.20181617.CrossRefPubMedPubMedCentral

31.

Requena DO, Garcia-Buitrago M. Molecular insights into colorectal carcinoma. Arch Med Res. 2020;51:839–44. https://doi.org/10.1016/j.arcmed.2020.09.014.CrossRefPubMed

32.

Lu D, et al. ACADSB regulates ferroptosis and affects the migration, invasion, and proliferation of colorectal cancer cells. Cell Biol Int. 2020;44:2334–43. https://doi.org/10.1002/cbin.11443.CrossRefPubMed

33.

Wang Q, et al. RNA binding protein DAZAP1 promotes HCC progression and regulates ferroptosis by interacting with SLC7A11 mRNA. Exp Cell Res. 2021;399: 112453. https://doi.org/10.1016/j.yexcr.2020.112453.CrossRefPubMed

34.

Huang HX, et al. TFAP2A is a novel regulator that modulates ferroptosis in gallbladder carcinoma cells via the Nrf2 signalling axis. Eur Rev Med Pharmacol Sci. 2020;24:4745–55. https://doi.org/10.26355/eurrev_202005_21163.CrossRefPubMed

35.

Wang X, et al. Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis. Toxicol Appl Pharmacol. 2021;410: 115363. https://doi.org/10.1016/j.taap.2020.115363.CrossRefPubMed

36.

Lu J, Xu F, Lu H. LncRNA PVT1 regulates ferroptosis through miR-214-mediated TFR1 and p53. Life Sci. 2020;260: 118305. https://doi.org/10.1016/j.lfs.2020.118305.CrossRefPubMed

37.

Mao C, et al. A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53. Cancer Res. 2018;78:3484–96. https://doi.org/10.1158/0008-5472.CAN-17-3454.CrossRefPubMedPubMedCentral

38.

Yang Y, et al. lncRNA ZFAS1 promotes lung fibroblast-to-myofibroblast transition and ferroptosis via functioning as a ceRNA through miR-150-5p/SLC38A1 axis. Aging. 2020;12:9085–102. https://doi.org/10.18632/aging.103176.CrossRefPubMedPubMedCentral

39.

Wang M, et al. Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ. 2019;26:2329–43. https://doi.org/10.1038/s41418-019-0304-y.CrossRefPubMedPubMedCentral

40.

Gai C, et al. MT1DP loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells. Cell Death Dis. 2020;11:751. https://doi.org/10.1038/s41419-020-02939-3.CrossRefPubMedPubMedCentral

41.

Zhang H, Chu K, Zheng C, Ren L, Tian R. Pseudogene DUXAP8 promotes cell proliferation and migration of hepatocellular carcinoma by sponging MiR-490-5p to induce BUB1 expression. Front Genet. 2020;11:666. https://doi.org/10.3389/fgene.2020.00666.CrossRefPubMedPubMedCentral

42.

Du C, Wang HX, Chen P, Chen CH. STAT3-induced upregulation of lncRNA DUXAP8 functions as ceRNA for miR-577 to promote the migration and invasion in colorectal cancer through the regulation of RAB14. Eur Rev Med Pharmacol Sci. 2019;23:6105–18. https://doi.org/10.26355/eurrev_201907_18424.CrossRefPubMed

43.

Yin D, Hua L, Wang J, Liu Y, Li X. Long non-coding RNA DUXAP8 facilitates cell viability, migration, and glycolysis in non-small-cell lung cancer via regulating HK2 and LDHA by inhibition of miR-409-3p. Onco Targets Ther. 2020;13:7111–23. https://doi.org/10.2147/OTT.S243542.CrossRefPubMedPubMedCentral

44.

He W, Yu Y, Huang W, Feng G, Li J. The pseudogene DUXAP8 promotes colorectal cancer cell proliferation, invasion, and migration by inducing epithelial-mesenchymal transition through interacting with EZH2 and H3K27me3. Onco Targets Ther. 2020;13:11059–70. https://doi.org/10.2147/OTT.S235643.CrossRefPubMedPubMedCentral

45.

Chen J, Lou W, Ding B, Wang X. Overexpressed pseudogenes, DUXAP8 and DUXAP9, promote growth of renal cell carcinoma and serve as unfavorable prognostic biomarkers. Aging. 2019;11:5666–88. https://doi.org/10.18632/aging.102152.CrossRefPubMedPubMedCentral

46.

Huang T, et al. Long non-coding RNA DUXAP8 enhances renal cell carcinoma progression via downregulating miR-126. Med Sci Monit. 2018;24:7340–7. https://doi.org/10.12659/MSM.910054.CrossRefPubMedPubMedCentral

47.

He RQ, et al. Prediction of clinical outcome and survival in soft-tissue sarcoma using a ten-lncRNA signature. Oncotarget. 2017;8:80336–47. https://doi.org/10.18632/oncotarget.18165.CrossRefPubMedPubMedCentral

48.

Su Y, et al. Construction of competitive endogenous RNA network and verification of 3-Key LncRNA signature associated with distant metastasis and poor prognosis in patients with clear cell renal cell carcinoma. Front Oncol. 2021;11: 640150. https://doi.org/10.3389/fonc.2021.640150.CrossRefPubMedPubMedCentral

49.

Cao W, Zhang HF, Ding XL, Zhu SZ, Zhou GX. The progression of pancreatic cancer cells is promoted by a long non-coding RNA LUCAT1 by activating AKT phosphorylation. Eur Rev Med Pharmacol Sci. 2021;25:738–48. https://doi.org/10.26355/eurrev_202101_24635.CrossRefPubMed

50.

Liu HZ, et al. LncRNA LUCAT1 promotes proliferation of ovarian cancer cells by regulating miR-199a-5p expression. Eur Rev Med Pharmacol Sci. 2020;24:1682–7. https://doi.org/10.26355/eurrev_202002_20342.CrossRefPubMed

51.

Chen Y, et al. Downregulation of long noncoding RNA LUCAT1 suppresses the migration and invasion of bladder cancer by targeting miR-181c-5p. Biomed Res Int. 2020;2020:4817608. https://doi.org/10.1155/2020/4817608.CrossRefPubMedPubMedCentral

52.

Zheng Z, et al. Long non-coding RNA LUCAT1 promotes proliferation and invasion in clear cell renal cell carcinoma through AKT/GSK-3beta signaling pathway. Cell Physiol Biochem. 2018;48:891–904. https://doi.org/10.1159/000491957.CrossRefPubMed

53.

Xiao H, et al. Long non-coding RNA Lucat1 is a poor prognostic factor and demonstrates malignant biological behavior in clear cell renal cell carcinoma. Oncotarget. 2017;8:113622–34. https://doi.org/10.18632/oncotarget.21185.CrossRefPubMedPubMedCentral

54.

He HT, et al. Biomarker and competing endogenous RNA potential of tumor-specific long noncoding RNA in chromophobe renal cell carcinoma. Onco Targets Ther. 2016;9:6399–406. https://doi.org/10.2147/OTT.S116392.CrossRefPubMedPubMedCentral

55.

Wang Y, Yan K, Wang L, Bi J. Genome instability-related long non-coding RNA in clear renal cell carcinoma determined using computational biology. BMC Cancer. 2021;21:727. https://doi.org/10.1186/s12885-021-08356-9.CrossRefPubMedPubMedCentral

56.

Khadirnaikar S, et al. Immune associated LncRNAs identify novel prognostic subtypes of renal clear cell carcinoma. Mol Carcinog. 2019;58:544–53. https://doi.org/10.1002/mc.22949.CrossRefPubMed

57.

Qi Y, et al. Tumor-infiltrating CD39(+)CD8(+) T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. Cancer Immunol Immunother. 2020;69:1565–76. https://doi.org/10.1007/s00262-020-02563-2.CrossRefPubMed

Title: Development and validation of ferroptosis-related lncRNAs prognosis signatures in kidney renal clear cell carcinoma
Authors: Xiao-Liang Xing
Zhi-Yong Yao
Jialan Ou
Chaoqun Xing
Feng Li
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02284-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Analyzing the whole-transcriptome profiles of ncRNAs and predicting the competing endogenous RNA networks in cervical cancer cell lines with cisplatin resistance

Identification and validation of a novel glycolysis-related gene signature for predicting the prognosis in ovarian cancer

Genistein as a regulator of signaling pathways and microRNAs in different types of cancers

Long noncoding RNA LINC00641 promotes renal cell carcinoma progression via sponging microRNA-340-5p

LncRNA HOXA-AS2 promotes glioblastoma carcinogenesis by targeting miR-885-5p/RBBP4 axis

Correction to: Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p

Keynote webinar | Spotlight on antibody–drug conjugates in cancer